FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations having received its cultivation license on October 13, 2017.

The October 9th ribbon-cutting ceremony was attended by local politicians and media, including Cobourg Mayor Gil Brocanier, with the Honourable Kim Rudd, MP for Northumberland and Peterborough South also expected to attend.

Thomas Fairfull, President and CEO, stated, "We welcome politicians and media to this momentous event where we begin converting the historic Certo building located at the former Kraft plant into a heritage museum and on-site dispensary. The Certo building is an important part of Cobourg's history and the Company intends to preserve this unique building. Today, we also begin construction of our flagship on-site dispensary, an important component of our business plan as we sit on the brink of adult-use legalization on October 17, 2018. The Company is preparing in earnest for sales of our high quality, indoor grown and pharmaceutical grade product, which will be available for sale shortly.”

The former Certo building was the first in the British Empire to make commercial grade pectin that was sold under the product name of "Certo" and is estimated at over 100 years old.

The property is listed on the municipal heritage register as a property of cultural heritage value.

Last year, Cobourg City Council endorsed several recommendations, including the designation of the Certo building under the Ontario Heritage Act as a building of cultural heritage value.

FSD Pharma through its wholly-owned subsidiary FV Pharma, is a licensed producer of marijuana under the Access to Cannabis for Medical Purposes Regulations having received its cultivation license on October 13, 2017.

FV Pharma management's mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world.

FV Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development.

The company recently signed an agreement with Canntab Therapeutics Ltd. to provide up to 10,000 sq. ft. of space for Canntab to develop its suite of novel cannabis oral delivery platforms.

Canntab will grant FSD Pharma 50% of the profits that it receives from any retail sales through FSD Pharma’s channels, as well as a 3.5% royalty on all Canntab products produced on-premise.

The shares began trading on the CSE on May 29th and are currently trading at $0.74.

For more information, please visit the company’s website, www.fsdpharma.com, or contact Thomas Fairfull, President and CEO at 905-686-7079 or email thomas.fairfull@fvpharma.com.